On February 7, 2023 Carina Biotech Pty Ltd (Carina), a cell therapy immuno-oncology company, reported that a poster presentation with preclinical data supporting the effectiveness of its LGR5-targeted CAR-T platform in ovarian cancer cell models will be presented at the 35th Annual Lorne Cancer Conference (Press release, Carina Biotech, FEB 7, 2023, View Source [SID1234626864]). Lorne Cancer 2023 will take place on February 9-11 in Lorne, Australia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation summarizes preclinical results of LGR5 CAR-T cells in two ovarian cancer models. The data shows that LGR5 CAR-T cells have significantly higher killing effects on OVCAR3 (an ovarian cancer cell line) and primary ovarian cancer cells compared to control T cells. In animal models, LGR5 CAR-T cells significantly decreased tumor burden. The data supports the conclusion that LGR5 CAR-T cells have potential to be developed as a novel immunotherapy for ovarian cancer.
"The data to be presented at Lorne Cancer 2023 regarding our lead LGR5 CAR-T cell therapy candidate provide further preclinical validation of our LGR5 CAR-T platform, supporting the effectiveness of LGR5 CAR-T in ovarian cancer models," said Deborah Rathjen, PhD, Carina’s Chief Executive Officer.
"Following the FDA green light on January 6 for our proposed clinical trial of our LGR5 CAR-T (CNA3103) in patients with metastatic colorectal cancer, we are working to initiate this trial as soon as possible. We are also encouraged by this latest data that suggests an additional indication for CNA3103" Dr Rathjen added.
Poster presentation details
Title: Development of Novel Ovarian Cancer Treatment Using CAR-T Cells Targeting LGR5
Poster Session III on February 11, 2023 at 1 PM AEDT
Presenter & Lead Author: Wanqi (Jady) Wang, Discipline of Obstetrics and Gynaecology, Adelaide Medical School, Robinson Research Institute, University of Adelaide
For more information about LGR5 and Carina Biotech’s clinical pipeline, visit www.carinabiotech.com.